Nouscom is a next-generation immunotherapy company developing engineered viral vectored vaccines for the treatment of cancer.

Nouscom

Nouscom is a private oncology company developing next generation immunotherapies. Nouscom’s proprietary technology platform, Exovax, harnesses the full power of immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators.
 
Nouscom is led by an experienced management team that has worked together for many years in previous successful enterprises, including IRBM/Merck and Okairos (acquired by GSK), and are veterans in the field of genetic vaccines.
 
Nouscom, which was founded in 2015 and is headquartered in Basel, Switzerland with operations in Rome, Italy, is backed by international life sciences investors: 5AM, Abingworth, LSP (Life Sciences Partners) and Versant Ventures.
 
For more information on Nouscom, please visit the company’s website at www.nouscom.com

Versant Ventures

EQT life science

LSP BioVentures

5AM Ventures

Abingworth

Nouscom AG

We are excited to attend the #JefferiesHealthcare conference June 7-9 in New York City where our CEO Marina Udier-Blagovic will present on Thursday at 8 am in Track 10. Nouscom AG is a clinical stage biotech developing off-the-shelf and personalized cancer vaccines. It uses a proprietary viral vector platform with capacity to encode for large number of neoantigens to safely and potently harness the power of the immune system. 6 clinical trials are actively ongoing, including a randomized Phase 2 trial of #NOUS-209 for the treatment of MSI-H solid tumors in combination with pembrolizumab, as well as #NOUS-PEV, a personalized cancer vaccines that reported Phase 1 data at American Association for Cancer Research 2023. Nouscom’s cancer vaccines induce potent and durable CD8 T cells, which are recruited to the tumor where they expand, diversify and drive tumor killing (D’Alise et al, #ScienceTranslationalMedicine 2022).

Nouscom is excited to attend the 9th Immuno-Oncology Innovation Forum #Sachs_IOIF on June 2 in Chicago where our CEO Marina Udier-Blagovic will join the panel discussing the future of neoantigen cancer vaccines. Nouscom’s proprietary platform based on viral vectors induces potent and durable CD8 T cell responses. These responses translate into clinical benefit for metastatic cancer patients, as demonstrated in multiple clinical trials (#NOUS-209, #NOUS-PEV released at American Association for Cancer Research 2023, Society for Immunotherapy of Cancer (SITC) 2022, American Society of Clinical Oncology (ASCO) 2022). CD8 T cells induced by the vaccine are recruited to the tumor where they proliferate and drive tumor killing (D’Alise et al,  #ScienceTranslationalMedicine 2022).

Nouscom announces the publication of a new manuscript on JITC, titled “Vector Aided Microenvironment programming (VAMP): reprogramming the TME with MVA virus expressing IL-12 for effective antitumor activity”, describing how Nouscom’s MVA encoding IL-12 is highly effective in preclinical tumor models resistant to the activity of checkpoint inhibitors, supporting its use as novel and more safe strategy to overcome TME mediated resistance to immunotherapy. 
https://lnkd.in/eb733NaV
#immunotherapy #nouscomag #viralvectors

Today we are presenting new positive translational Phase 1b data of NOUS-PEV, our personalized neoantigen cancer immunotherapy, in a late-breaking abstract session at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida. 
 
The session entitled ‘Late-Breaking Research: Clinical Research 2’ will take place at 9:00 AM – 12:30 PM EDT. 
 
Find out more: https://lnkd.in/eEsTadK8
 
View the full abstract: https://lnkd.in/eCHzg9p5 
 
#NOUSPEV #oncology #AACR23

We will be presenting a Late-breaking abstract at the 2023 American Association for Cancer Research Annual Meeting on 18th April 2023, 9:00 am - 12:30 pm EDT in Orlando, Florida. 
 
The abstract will reveal new translational data from the ongoing Phase 1b trial evaluating NOUS-PEV in patients with metastatic melanoma. 
 
For more details: https://lnkd.in/eKWBQeJS
 
#NOUSPEV #oncology #AACR23

Today is International Women's Day 2023, a global day to celebrate the social, economic, cultural and political achievements of women. At Nouscom, we are proud to support equal opportunities for women in the biotech industry, with 85% of our employees being female. Further, we are delighted to announce the following promotions of 3 of our female employees: 
·      Loredana Siani to Vice President, Technical and CMC Development 
·      Tiffany Brooke Muller to Senior Vice President, Finance 
·      Morena D’Alise to Vice President, Immunology 
 
Find out more about the global movement in which this year’s theme is #EmbraceEquity and marks a call to action to accelerate women’s equality: https://lnkd.in/dGX7T8X 
  
#IWD23

Join us in welcoming Sarah Runswick as our Senior Director, Clinical Science.
She is an experienced global clinical scientist with over 20 years expertise in early and late stage Oncology Clinical trial development and delivery, including successful regulatory submission experience and leading investigator study strategy programs.
https://lnkd.in/exiBD5Rz

#people #biotech #immunotherapy

March is Colorectal Cancer Awareness month. 
 
Colorectal cancer is the second deadliest cancer in Europe and the US. Colorectal cancer can be prevented by identifying and removing polyps early before developing into cancer. At Nouscom, we want to raise awareness of colorectal cancer and encourage regular screening to identify colorectal polyps or cancer earlier to allow the best chances of successful treatment. 
 
Find out more about Colorectal Cancer Awareness Month: https://lnkd.in/dMSUMKg 

#colorectalcancer #oncology #cancerawareness

Join us in welcoming Yen-Ching Chua as our Vice President, Clinical Operations. 
She is an experienced global clinical operations leader with over 20 years expertise in leading Pharmaceutical Development Operations 
including Quality Assurance and Pharmacovigilance.
https://lnkd.in/eAiqTxQU

#people #biotech #immunotherapy

We are delighted to announce the first patient has been dosed in the Phase 2 trial evaluating our lead product, NOUS-209, an ‘off-the shelf’ neoantigen cancer immunotherapy in dMMR/MSI-High metastatic colorectal cancer. 
 
Read the full PR here: https://lnkd.in/eTCtSbJw
 
#oncology #clinicaltrial #immunotherapy

COM:NOUSCOM

Nouscom